Vascular

Intuitive Surgical, Inc. has announced that it received FDA clearance to market its EndoWrist® One™ Vessel Sealer instrument for use with the da Vinci® Si™ Surgical System.

C. R. Bard, Inc’s acquisition of Lutonix, Inc will position it well to be the first company to gain FDA clearance for a drug coated PTA balloon in what is estimated could be a $1Bn market.

Cook Medical, is to invest up to €16.5m over four years creating highly skilled positions in Research and Development activities at its Limerick site, with Government support through IDA Ireland.

Dutch Haemostasis and Regenerative Medicine company ProFibrix B.V., has announced that its U.S. multicenter Phase II clinical trial with Fibrocaps in spinal, peripheral vascular and general surgery resulted in a highly statistically significant reduction in mean time to haemostasis and incidence of haemostasis at 3, 5 and 10 minutes, as compared to active control.

TriReme Medical, Inc.has received 510(K) FDA approval to market its “Chocolate” PTA balloon catheter for the treatment of occluded peripheral arteries in the United States.

STERIS Corporation and Toshiba America Medical Systems, Inc.have formed an alliance to offer advanced vascular, cardiovascular, pediatric and neurosurgical hybrid surgical suites.

Boston Scientific’s Promus Element Drug Eluting Stent was approved by FDA in late November and now the agency has demanded that the company includes a warning on its packaging about the risk of stent shrinkage.

Kensey Nash Corporation and St. Jude Medical will enter into non-binding mediation in an attempt to resolve disputes over royalty payments to Kensey Nash relating to the Angio-Seal vascular closure device, as well as other related claims.

Boston researchers have found that less than 10% of retrievable IVC filters were removed from patients, despite the fact that the indication for the filter placement was no longer present at discharge.

Boston Scientific launchea CHARGER™ PTA Balloon catheter in USA and Infinion 16, first and only 16-contact percutaneous lead for treatment of patients suffering chronic pain.

Cambridge Technology Showcase: Reducing incidence of falls in the elderly, bringing cheap diagnosis of killer diseases, aid for physios with sophisticated gait analysis, coatings for medical devices to reduce biofilms.

Covidien has announced that the U.S. Food and Drug Administration (FDA) has expanded the cope of approval for its SpiderFX® embolic protection device to include the treatment of severely calcified lesions used in conjunction with plaque excision in arteries of the lower extremities.

Most Significant Growth In Clot Management Market Will Be in Mechanical Thrombectomy Procedures, According to Millennium Research Group.

The tenth running of the Multidisciplinary European Endovascular Therapy (MEET) congress will be held in Rome on December 1st-3rd, at the Crowne Plaza St Peters Hotel.

Device Innovations, Including Drug-Coated Balloons and Drug-Eluting Stents, Will Help Drive Growth, According to Millennium Research Group

Neovasc Inc. has announced that it has received the CE mark designation for its Reducer™ product for the treatment of refractory angina.